State of New Jersey Common Pension Fund D Takes Position in Supernus Pharmaceuticals, Inc. $SUPN

State of New Jersey Common Pension Fund D bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 19,139 shares of the specialty pharmaceutical company’s stock, valued at approximately $951,000.

A number of other hedge funds have also added to or reduced their stakes in SUPN. Royal Bank of Canada lifted its position in Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after buying an additional 4,729 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after acquiring an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after acquiring an additional 1,297 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 370.5% in the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after acquiring an additional 112,886 shares in the last quarter. Finally, Empowered Funds LLC increased its position in shares of Supernus Pharmaceuticals by 16.0% in the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 6,619 shares during the last quarter.

Insider Activity at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 4,475 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jack A. Khattar sold 35,000 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the sale, the chief executive officer directly owned 958,100 shares of the company’s stock, valued at $48,259,497. This represents a 3.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 120,881 shares of company stock worth $6,139,356 in the last three months. 8.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on SUPN shares. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $49.37 on Tuesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $30.83 and a 52-week high of $59.68. The company has a market capitalization of $2.87 billion, a P/E ratio of -96.80, a price-to-earnings-growth ratio of 1.11 and a beta of 0.57. The company has a 50-day simple moving average of $50.88 and a 200 day simple moving average of $49.92.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.